Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study

Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee, Dae Jung Kim, Hyeon Chang Kim

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Aim: To compare the risks of hospitalization for heart failure (HHF) associated with sulfonylurea (SU), dipeptidyl peptidase-4 inhibitor (DPP-4i), and thiazolidinedione (TZD) as add-on medications to metformin (MET) therapy using the data of Korean adults with type-2 diabetes from the Korean National Health Insurance database. Methods: We identified 98,383 people who received SU (n = 42,683), DPP-4i (n = 50,310), or TZD (n = 5,390) added to initial treatment of MET monotherapy in patients with type-2 diabetes. The main outcome was the hospitalization for HHF. Hazard ratios for HHF by type of second-line glucose-lowering medication were estimated by Cox-proportional hazard models. Sex, age, duration of MET monotherapy, Charlson Comorbidity Index and additional comor-bidities, and calendar year were controlled as potential confounders. Results: The observed numbers (rate per 100,000 person-years) of HHF events were 1,129 (658) for MET+SU users, 710 (455) for MET+DPP-4i users, and 110 (570) for MET+TZD users. Compared to that for MET+SU users (reference group), the adjusted hazard ratios for HHF events were 0.76 (95% confidence interval 0.69-0.84) for MET+DPP-4i users and 0.96 (95% confidence interval 0.79-1.17) for MET+TZD users. Conclusion: DPP-4i as an add-on therapy to MET may lower the risks of HHF compared with SU.

Original languageEnglish
Article numbere0211959
JournalPloS one
Volume14
Issue number2
DOIs
Publication statusPublished - 2019 Feb

Bibliographical note

Funding Information:
This research was supported by a grant of the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HI13C0715). KHIDI(https://www.khidi.or.kr/eps) the Ministry of Health and Welfare, Republic of Korea (http://www.mohw.go.kr/) The funder provided support in the form of salaries for authors DJ Kim, HC Kim. NO - The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2019 Lee et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study'. Together they form a unique fingerprint.

Cite this